Xenon(US:XENE) Globenewswire·2025-10-27 12:30Company Overview - Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of therapeutics for patients in need [3] - The company is advancing its lead molecule, azetukalner, which is a selective Kv7 potassium channel opener currently in Phase 3 clinical trials for epilepsy, major depressive disorder (MDD), and bipolar depression (BPD) [3] - Additionally, Xenon is developing an early-stage portfolio of potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for pain treatment [3] Upcoming Financial Results - Xenon Pharmaceuticals will report its third quarter 2025 financial results and provide a business update after the close of U.S. financial markets on November 3, 2025 [1] - A conference call and webcast will take place on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time) [2] Contact Information - Colleen Alabiso is the Senior Vice President of Corporate Affairs, and can be reached at (617) 671-9238 [5] - Media inquiries can be directed to media@xenon-pharma.com, while investor inquiries can be sent to investors@xenon-pharma.com [5]